mTOR: Role in cancer, metastasis and drug resistance

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

mTOR Signaling in Growth, Metabolism, and Disease

Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555

Epithelial–mesenchymal transitions in tumour progression

Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

Rho GTPases and the Actin Cytoskeleton

Hall, A. (1998) · Science · doi:10.1126/science.279.5350.509 · Cited by 6,138

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807

TOR signaling in growth and metabolism

Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645

Targeting RAS signalling pathways in cancer therapy

Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354

Patterns of somatic mutation in human cancer genomes

Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα

Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,874

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097

A mammalian protein targeted by G1-arresting rapamycin–receptor complex

Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,010

Phosphatidylinositol-3-OH kinase direct target of Ras

Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

Jiao, Y., Shi, C., Edil, B. H., de Wilde, R. F., Klimstra, D. S., Maitra, A., Schulick, R. D., Tang, L. H., Wolfgang, C. L., Choti, M. A., et al. (2011) · Science · doi:10.1126/science.1200609 · Cited by 1,744

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

Vézina, C., KUDELSKI, A., & Sehgal, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,691

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555

RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,471

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384

FOXO transcription factors at the interface between longevity and tumor suppression

Greer, E. L., & Brunet, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209086 · Cited by 1,340

mTOR and cancer: insights into a complex relationship

Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A. V., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,309

Phosphorylation and Functional Inactivation of TSC2 by Erk

Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,250

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., & Sabatini, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1432 · Cited by 1,130

mTOR as a central hub of nutrient signalling and cell growth

Kim, J., & Guan, K. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0205-1 · Cited by 1,094

mTOR signalling and cellular metabolism are mutual determinants in cancer

Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088

The mTOR‐regulated phosphoproteome reveals a mechanism of mTORC1‐mediated inhibition of growth factor signaling

Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084

mTOR kinase structure, mechanism and regulation

Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013) · Nature · doi:10.1038/nature12122 · Cited by 1,075

PKB/Akt

Lawlor, M. A., & Alessi, D. R. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.16.2903 · Cited by 1,068

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991

Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells

Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Bissler, J. J., Kingswood, J. C., Radzikowska, E., Zonnenberg, B. A., Frost, M., Белоусова, Е. Д., Sauter, M., Nonomura, N., Brakemeier, S., de Vries, P. J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61767-x · Cited by 880

Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling

Yu, Y., Yoon, S.-O., Poulogiannis, G., Yang, Q., Ma, X. M., Villén, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., et al. (2011) · Science · doi:10.1126/science.1199484 · Cited by 864

PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

Corless, C. L., Schroeder, A., Griffith, D., Town, A., McGreevey, L. S., Harrell, P. M., Shiraga, S., Bainbridge, T., Morich, J. R., & Heinrich, M. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.068 · Cited by 847

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 829

Autophagy as a target for anticancer therapy

Jankú, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.71 · Cited by 814

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61134-9 · Cited by 794

eIF-4E expression and its role in malignancies and metastases

Benedetti, A. D., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 751

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas

Cappellen, D., de Oliveira, C. C. B., Ricol, D., de Medina, S. D., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 743

A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

Sekulić, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Karnitz, L. M., & Abraham, R. T. (2000) · PubMed · Cited by 708

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706

Control of p70 S6 kinase by kinase activity of FRAP in vivo

Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al‐Ahmadie, H. A., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 697

Class I PI3K in oncogenic cellular transformation

Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 612

Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway

Lamouille, S., & Derynck, R. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611146 · Cited by 596

Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation.

Rodriguez‐Viciana, P., Warne, P. H., Vanhaesebroeck, B., Waterfield, M. D., & Downward, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00602.x · Cited by 566

Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.

Chen, J., Zheng, X. F., Brown, E. J., & Schreiber, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4947 · Cited by 556

Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40

Yang, H., Jiang, X., Li, B., Yang, H. J., Miller, M., Yang, A., Dhar, A., & Pavletich, N. P. (2017) · Nature · doi:10.1038/nature25023 · Cited by 548

Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control

Oldham, S., & Hafen, E. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)00042-9 · Cited by 547

mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways

Gulhati, P., Bowen, K. A., Liu, J., Stevens, P. D., Rychahou, P. G., Chen, M., Lee, E. Y., Weiss, H. L., O’Connor, K. L., Gao, T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4058 · Cited by 544

Twenty-five years of mTOR: Uncovering the link from nutrients to growth

Sabatini, D. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716173114 · Cited by 525

Regulation of eIF-4E BP1 Phosphorylation by mTOR

Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K. I., Weng, Q.-P., Kasuga, M., Nishimoto, I., & Avruch, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26457 · Cited by 522

PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints

Keith, C. T., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.270.5233.50 · Cited by 521

Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy

Lim, J. S., Kim, W.-I., Kang, H., Kim, S. H., Park, A. H., Park, E. K., Cho, Y., Kim, H. M., Kim, J. A., Kim, J. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3824 · Cited by 518

Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance

Hatanpaa, K. J., Burma, S., Zhao, D., & Habib, A. A. (2010) · Neoplasia · doi:10.1593/neo.10688 · Cited by 484

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Grabiner, B. C., Nardi, V., Birsoy, K., Possemato, R., Shen, K., Sinha, S., Jordan, A. C., Beck, A. H., & Sabatini, D. M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0929 · Cited by 470

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465

Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer

Davies, H. R., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G. R., Teague, J. W., Butler, A. P., Edkins, S., Stevens, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1855 · Cited by 464

mTORC1 and mTORC2 in cancer and the tumor microenvironment

Kim, L. C., Cook, R. S., & Chen, J. (2016) · Oncogene · doi:10.1038/onc.2016.363 · Cited by 463

mTOR in aging, metabolism, and cancer

Cornu, M., Albert, V., & Hall, M. N. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.12.005 · Cited by 455

mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling

Julien, L.-A., Carriere, A., Moreau, J., & Roux, P. P. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00601-09 · Cited by 452

Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1

Sofer, A., Lei, K., Johannessen, C. M., & Ellisen, L. W. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.5834-5845.2005 · Cited by 449

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442

PtdIns(3,4,5) P 3-Dependent Activation of the mTORC2 Kinase Complex

Liu, P., Gan, W., Chin, Y. R., Ogura, K., Guo, J., Zhang, J., Wang, B., Blenis, J., Cantley, L. C., Toker, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0460 · Cited by 403

Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors

Wagner, A. J., Malinowska-Kołodziej, I., Morgan, J. A., Qin, W., Fletcher, C. D. �., Vena, N., Ligon, A. H., Antonescu, C. R., Ramaiya, N. H., Demetri, G. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2981 · Cited by 399

Untitled work

(1992) · PubMed · Cited by 383

Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing

Kunstman, J. W., Juhlin, C. C., Goh, G., Brown, T. C., Stenman, A., Healy, J. M., Rubinstein, J. C., Choi, M., Kiss, N. B., Nelson-Williams, C. J., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu749 · Cited by 366

Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation

Carrière, A., Cargnello, M., Julien, L.-A., Gao, H., Bonneil, É., Thibault, P., & Roux, P. P. (2008) · Current Biology · doi:10.1016/j.cub.2008.07.078 · Cited by 348

The TOR pathway comes of age

Stanfel, M. N., Shamieh, L. S., Kaeberlein, M. R., & Kennedy, B. K. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.06.007 · Cited by 347

Drug-sensitive FGFR2 mutations in endometrial carcinoma

Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345

Architecture of human mTOR complex 1

Aylett, C. H. S., Sauer, E., Imseng, S., Boehringer, D., Hall, M. N., Ban, N., & Maier, T. (2016) · Science · doi:10.1126/science.aaa3870 · Cited by 344

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Wagle, N., Grabiner, B. C., Allen, E. M. V., Amin‐Mansour, A., Taylor-Weiner, A. N., Rosenberg, M. W., Gray, N. S., Barletta, J. A., Guo, Y., Swanson, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403352 · Cited by 321

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

Pollock, P. M., Gartside, M. G., Dejeza, L. C., Powell, M. A., Mallon, M. A., Cancer Genome Project, Davies, H. R., Mohammadi, M., Futreal, P. A., Stratton, M. R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210529 · Cited by 311

TGF-β-induced activation of mTOR complex 2 drives epithelial–mesenchymal transition and cell invasion

Lamouille, S., Connolly, E. C., Smyth, J. W., Akhurst, R. J., & Derynck, R. (2012) · Journal of Cell Science · doi:10.1242/jcs.095299 · Cited by 310

Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial

Davies, D. M., de Vries, P. J., Johnson, S. R., McCartney, D. L., Cox, J. A., Serra, A. L., Watson, P., Howe, C. J., Doyle, T., Pointon, K. S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0445 · Cited by 305

Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

Bärlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y.-D., Bittner, M. L., Torhorst, J., Haas, P., Bucher, C., Sauter, G., et al. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1252 · Cited by 305

Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma

Li, Y. Y., Hanna, G. J., Laga, A. C., Haddad, R. I., Lorch, J. H., & Hammerman, P. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1773 · Cited by 300

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood · doi:10.1182/blood.v97.3.729 · Cited by 289

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

Wagle, N., Grabiner, B. C., Allen, E. M. V., Hodis, E., Jacobus, S. J., Supko, J. G., Stewart, M. L., Choueiri, T. K., Gandhi, L., Cleary, J. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0353 · Cited by 282

4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications

Armengol, G., Rojo, F., Castellví, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J. M., & y Cajal, S. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0881 · Cited by 279

Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer

Meyer, K. B., Maia, A.-T., O’Reilly, M., Teschendorff, A. E., Chin, S., Caldas, C., & Ponder, B. A. J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060108 · Cited by 277

Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.

Jang, J., Shin, K., & Park, J.-G. (2001) · PubMed · Cited by 273

Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis

Huang, S., & Zhou, H. (2011) · Current Protein and Peptide Science · doi:10.2174/138920311795659407 · Cited by 270

A comprehensive map of the mTOR signaling network

Caron, É., Ghosh, S., Matsuoka, Y., Ashton‐Beaucage, D., Therrien, M., Lemieux, S., Perreault, C., Roux, P. P., & Kitano, H. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.108 · Cited by 248

Wide spectrum of developmental brain disorders from megalencephaly to focal cortical dysplasia and pigmentary mosaicism caused by mutations of MTOR

Mirzaa, G., Campbell, C., Solovieff, N., Goold, C. P., Jansen, L., Menon, S., Timms, A., Conti, V., Biag, J., Adams, C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0363 · Cited by 246

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

Demetri, G. D., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui-Nguyen, B., Cranmer, L. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5766 · Cited by 245

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

Jankú, F., Hong, D. S., Fu, S., Piha-Paul, S. A., Naing, A., Falchook, G. S., Tsimberidou, A. M., Stepanek, V. M. T., Moulder, S., Lee, J. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.035 · Cited by 237

Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer

Gelsi‐Boyer, V., Orsetti, B., Cervera, N., Finetti, P., Sircoulomb, F., Rougé, C., Lasorsa, L., Letessier, A., Ginestier, C., Monville, F., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0128 · Cited by 237

TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin

Lorenz, M. C., & Heitman, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27531 · Cited by 236

Tor Kinases Are in Distinct Membrane-associated Protein Complexes inSaccharomyces cerevisiae

Wedaman, K. P., Reinke, A. W., Anderson, S., Yates, J. R., McCaffery, J. M., & Powers, T. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-09-0609 · Cited by 232

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 223

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

McKay, J., Murray, L. J., Curran, S., Ross, V. G., Clark, C., Murray, G. I., Cassidy, J., & McLeod, H. L. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00234-4 · Cited by 220

PIK3CA in cancer: The past 30 years

Arafeh, R., & Samuels, Y. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.002 · Cited by 220

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

Meric‐Bernstam, F., Akçakanat, A., Chen, H., Do, K.-A., Sangai, T., Adkins, F. C., Gonzalez-Angulo, A. M., Rashid, A., Crosby, K., Dong, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2123 · Cited by 212

Prostate cancer, PI3K, PTEN and prognosis

Wise, H. M., Hermida, M. A., & Leslie, N. R. (2017) · Clinical Science · doi:10.1042/cs20160026 · Cited by 212

Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors

Ballif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J., & Gygi, S. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409143102 · Cited by 211

Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction

Corvera, S. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01366-x · Cited by 206

SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling

Blattner, M., Liu, D., Robinson, B. D., Huang, D., Poliakov, A., Gao, D., Nataraj, S., Deonarine, L. D., Augello, M. A., Sailer, V., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.004 · Cited by 204

Somatic Mutations in the MTOR gene cause focal cortical dysplasia type II b

Nakashima, M., Saitsu, H., Takei, N., Tohyama, J., Kato, M., Kitaura, H., Shiina, M., Shirozu, H., Masuda, H., Watanabe, K., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24444 · Cited by 198

RTP801 Is Elevated in Parkinson Brain Substantia Nigral Neurons and Mediates Death in Cellular Models of Parkinson's Disease by a Mechanism Involving Mammalian Target of Rapamycin Inactivation

Malagelada, C., Ryu, E. J., Biswas, S. C., Jackson-Lewis, V. R., & Greene, L. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3292-06.2006 · Cited by 190

Mechanisms of FGFR-mediated carcinogenesis

Ahmad, I., Iwata, T., & Leung, H. Y. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.004 · Cited by 188

Rapamycin‐mediated mTORC 2 inhibition is determined by the relative expression of FK 506‐binding proteins

Schreiber, K. H., Ortiz, D., Academia, E. C., Anies, A. C., Liao, C., & Kennedy, B. K. (2015) · Aging Cell · doi:10.1111/acel.12313 · Cited by 183

A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma

Fan, Q., Aksoy, O., Wong, R. A., Ilkhanizadeh, S., Novotny, C. J., Gustafson, W. C., Truong, A. Y.-Q., Cayanan, G., Simonds, E. F., Haas-Kogan, D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.014 · Cited by 180

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumorsPreprint

Robbins, C. M., Tembe, W. A., Baker, A. S., Sinari, S. A., Moses, T. Y., Beckstrom‐Sternberg, S. M., Beckstrom-Sternberg, J., Barrett, M. T., Long, J. P., Chinnaiyan, A. M., et al. (2010) · Genome Research · doi:10.1101/gr.107961.110 · Cited by 179

Caffeine Targets TOR Complex I and Provides Evidence for a Regulatory Link between the FRB and Kinase Domains of Tor1p

Reinke, A. W., Chen, J. C.-Y., Aronova, S., & Powers, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603107200 · Cited by 179

TORC2 Structure and Function

Gaubitz, C., Prouteau, M., Kuśmider, B., & Loewith, R. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.04.001 · Cited by 163

Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas

Rand, V., Huang, J., Stockwell, T., Ferriera, S., Buzko, O. V., Lévy, S., Busam, D., Li, K., Edwards, J. B., Eberhart, C. G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507200102 · Cited by 160

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

van Rhijn, B. V., van Tilborg, A. V., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J., van der Kwast, T., Zwarthoff, E., & Radvanyi, F. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200883 · Cited by 155

The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2

Kovalski, J. R., Bhaduri, A., Zehnder, A. M., Neela, P. H., Che, Y., Wozniak, G. G., & Khavari, P. A. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.001 · Cited by 154

Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations

Roumiantsev, S., Krause, D. S., Neumann, C. A., Dimitri, C. A., Asiedu, F., Cross, N. C. P., & Etten, R. A. V. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00053-4 · Cited by 152

Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy

Møller, R. S., Weckhuysen, S., Chipaux, M., Marsan, E., Taly, V., Bebin, E. M., Hiatt, S. M., Prokop, J. W., Bowling, K. M., Mei, D., et al. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000118 · Cited by 152

PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth

Sharma, N., Nanta, R., Sharma, J. P., Gunewardena, S., Singh, K. P., Shankar, S., & Srivastava, R. K. (2015) · Oncotarget · doi:10.18632/oncotarget.5055 · Cited by 151

Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit

Chan, T. O., Rodeck, U., Chan, A. M.-L., Kimmelman, A. C., Rittenhouse-Simmons, S., Panayotou, G., & Tsichlis, P. N. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00033-8 · Cited by 150

mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR

Yin, Y., Hua, H. M., Li, M., Liu, S., Kong, Q., Shao, T., Wang, J., Luo, Y., Wang, Q., Luo, T. L., et al. (2015) · Cell Research · doi:10.1038/cr.2015.133 · Cited by 147

Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells

Urano, J., Sato, T., Matsuo, T., Otsubo, Y., Yamamoto, M. P., & Tamanoi, F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608510104 · Cited by 140

Cryo-EM structure of human mTOR complex 2

Chen, X., Liu, M., Tian, Y., Li, J., Qi, Y., Zhao, D., Wu, Z., Huang, M., Wong, C. C. L., Wang, H., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0029-3 · Cited by 138

Down‐regulation of placental mTOR, insulin/IGF‐I signaling, and nutrient transporters in response to maternal nutrient restriction in the baboon

Kavitha, J., Rosario, F. J., Nijland, M. J., McDonald, T. J., Wu, G., Kanai, Y., Powell, T. L., Nathanielsz, P. W., & Jansson, T. (2013) · The FASEB Journal · doi:10.1096/fj.13-242271 · Cited by 135

Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors

Zhao, J., Roth, J., Bode‐Lesniewska, B., Pfaltz, M., Heitz, P. U., & Komminoth, P. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10035 · Cited by 132

Vorinostat-An overview

Bubna, A. (2015) · Indian Journal of Dermatology · doi:10.4103/0019-5154.160511 · Cited by 131

Amplification of thePlatelet-Derived Growth Factor Receptor-A(PDGFRA) Gene Occurs in Oligodendrogliomas with Grade IV Anaplastic Features

Smith, J. S., Wang, X.-Y., Qian, J., Hosek, S. M., Scheithauer, B. W., Jenkins, R. B., & James, C. D. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.495 · Cited by 125

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

Lindblad, O., Cordero, E., Puissant, A., Macaulay, L., Ramos, A. H., Kabir, N. N., Sun, J., Vallon‐Christersson, J., Haraldsson, K., Hemann, M. T., et al. (2016) · Oncogene · doi:10.1038/onc.2016.41 · Cited by 124

Akt Contributes to Activation of the TRIF-Dependent Signaling Pathways of TLRs by Interacting with TANK-Binding Kinase 1

Joung, S. M., Park, Z., Rani, S., Takeuchi, O., Akira, S., & Lee, J. Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903534 · Cited by 123

CONVERSION TO RAPAMYCIN IMMUNOSUPPRESSION IN RENAL TRANSPLANT RECIPIENTS: REPORT OF AN INITIAL EXPERIENCE1

Domínguez, J., Mahalati, K., KIBERD, B. A., McAlister, V. C., & MacDonald, A. S. (2000) · Transplantation · doi:10.1097/00007890-200010270-00021 · Cited by 123

Long noncoding RNAs: emerging players in thyroid cancer pathogenesis

Murugan, A. K., Munirajan, A. K., & Alzahrani, A. S. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0188 · Cited by 120

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

Mahalingam, D., Medina, E. C., Esquivel, J., Espitia, C. M., Smith, S. A., Oberheu, K., Swords, R. T., Kelly, K. R., Mita, M. M., Mita, A. C., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1385 · Cited by 118

New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases

Toffalini, F., & Demoulin, J. (2010) · Blood · doi:10.1182/blood-2010-04-279752 · Cited by 104

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin

Xu, J., Pham, C. G., Albanese, S. K., Dong, Y., Oyama, T., Lee, C., Rodrik-Outmezguine, V. S., Yao, Z., Han, S. I., Chen, D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86120 · Cited by 100

4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1

Yang, H., Wang, J., Liu, M., Chen, X., Huang, M., Tan, D., Dong, M.-Q., Wong, C. C. L., Wang, J., Xu, Y., et al. (2016) · Protein & Cell · doi:10.1007/s13238-016-0346-6 · Cited by 96

m TORC 2‐ SGK ‐1 acts in two environmentally responsive pathways with opposing effects on longevity

Mizunuma, M., Neumann‐Haefelin, E., Moroz, N., Li, Y., & Blackwell, T. K. (2014) · Aging Cell · doi:10.1111/acel.12248 · Cited by 92

Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.

Yagasaki, F., Wakao, D., Yokoyama, Y., Uchida, Y., MUROHASHI, I., Kayano, H., Taniwaki, M., Matsuda, A., & Bessho, M. (2001) · PubMed · Cited by 92

An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival

Edinger, A. L., & Thompson, C. B. (2004) · Oncogene · doi:10.1038/sj.onc.1207738 · Cited by 91

mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome

Klümpen, H., Queiroz, K. C. S., Spek, C. A., van Noesel, C. J. M., Brink, H. C., de Leng, W. W. J., de Wilde, R. F., Mathus-Vliegen, E. M. H., Offerhaus, G. J. A., Alleman, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7825 · Cited by 88

Expression of the FGFR1 gene in human breast‐carcinoma cells

Jacquemier, J. D., Adélaı̈de, J., Parc, P., Penault-Llorca, F. M., Planche, J., deLapeyrière, O., & Birnbaum, D. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590314 · Cited by 86

PIKKs — the solenoid nest where partners and kinases meet

Baretić, D., & Williams, R. L. (2014) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2014.11.003 · Cited by 85

Rapalogs in cancer prevention

Blagosklonny, M. V. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.22859 · Cited by 83

Weekly nab -Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial

Gonzalez-Angulo, A. M., Meric‐Bernstam, F., Chawla, S. P., Falchook, G. S., Hong, D. S., Akçakanat, A., Chen, H., Naing, A., Fu, S., Wheler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3110 · Cited by 82

Tor forms a dimer through an N-terminal helical solenoid with a complex topology

Baretić, D., Berndt, A., Ohashi, Y., Johnson, C. M., & Williams, R. L. (2016) · Nature Communications · doi:10.1038/ncomms11016 · Cited by 82

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Kong, Y., Si, L., Li, Y., Wu, X., Xu, X., Dai, J., Tang, H., Ma, M., Chi, Z., Sheng, X., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1110 · Cited by 81

Structural Analysis and Functional Implications of the Negative mTORC1 Regulator REDD1,

Vega-Rubín-de-Celis, S., Abdallah, Z., Kinch, L. N., Grishin, N. V., Brugarolas, J., & Zhang, X. (2010) · Biochemistry · doi:10.1021/bi902135e · Cited by 81

mTOR Signaling Confers Resistance to Targeted Cancer Drugs

Guri, Y., & Hall, M. N. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.10.006 · Cited by 81

Hemispheric cortical dysplasia secondary to a mosaic somatic mutation in MTOR

Leventer, R. J., Scerri, T. S., Marsh, A. P. L., Pope, K., Gillies, G., Maixner, W. J., MacGregor, D. P., Harvey, A. S., Delatycki, M. B., Amor, D. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001594 · Cited by 80

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma

Ghosh, A. P., Marshall, C. B., Coric, T., Shim, E., Kirkman, R. L., Ballestas, M. E., Ikura, M., Bjornsti, M., & Sudarshan, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4963 · Cited by 78

Fibrinogen promotes malignant biological tumor behavior involving epithelial–mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma

Zhang, F., Wang, Y., Sun, P., Wang, Z.-Q., Wang, D., Zhang, D.-S., Wang, F.-H., Fu, J., Xu, R., & Li, Y. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2493-4 · Cited by 77

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies

Ip, C. K. M., Ng, P. K., Jeong, K. J., Shao, S. H., Ju, Z., Leonard, P. G., Hua, X., Vellano, C. P., Woessner, R. D., Sahni, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06949-w · Cited by 77

Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin.

Kumabe, T., SOHMA, Y., Kayama, T., Yoshimoto, T., & Yamamoto, T. (1992) · PubMed · Cited by 75

FGFR3 mutations in prostate cancer: association with low-grade tumors

Hernandez, S. F., de Muga, S., Agell, L., Juanpere-Rodero, N., Esgueva, R., Lorente, J. A., Mojal, S., Serrano, S., & Lloreta, J. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.46 · Cited by 75

Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition

Zong, H., Yin, B., Zhou, H., Cai, D., Ma, B., & Xiang, Y. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3321-4 · Cited by 75

Genetic deregulation of the PIK3CA oncogene in oral cancer

Murugan, A. K., Munirajan, A. K., & Tsuchida, N. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.005 · Cited by 73

Isolation of Hyperactive Mutants of Mammalian Target of Rapamycin

Ohne, Y., Takahara, T., Hatakeyama, R., Matsuzaki, T., Noda, M., Mizushima, N., & Maeda, T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801546200 · Cited by 70

The prospect of precision therapy for renal cell carcinoma

Ciccarese, C., Brunelli, M., Montironi, R., Fiorentino, M., Iacovelli, R., Heng, D. Y. C., Tortora, G., & Massari, F. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.07.003 · Cited by 68

TRIM44 promotes proliferation and metastasis in non-small cell lung cancer via mTOR signaling pathway

Xing, Y., Meng, Q., Chen, X., Zhao, Y., Liu, W., Hu, J., Xue, F., Wang, X., & Cai, L. (2016) · Oncotarget · doi:10.18632/oncotarget.8586 · Cited by 62

S6K1 Plays a Key Role in Glial Transformation

Nakamura, J. L., Garcia, E., & Pieper, R. O. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6188 · Cited by 61

Infiltrating macrophages increase RCC epithelial mesenchymal transition (EMT) and stem cell-like populations via AKT and mTOR signaling

Yang, Z., Xie, H., He, D., & Li, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9873 · Cited by 59

Cryo-EM structure of Saccharomyces cerevisiae target of rapamycin complex 2

Karuppasamy, M., Kuśmider, B., de Oliveira, T. M., Gaubitz, C., Prouteau, M., Loewith, R., & Schaffitzel, C. (2017) · Nature Communications · doi:10.1038/s41467-017-01862-0 · Cited by 59

BMP2 promotes proliferation and invasion of nasopharyngeal carcinoma cells via mTORC1 pathway

Wang, M.-H., Zhou, X.-M., Zhang, M.-Y., Shi, L. D., Xiao, R.-W., Zeng, L.-S., Yang, X.-Z., Zheng, X., Wang, H., & Mai, S. (2017) · Aging · doi:10.18632/aging.101230 · Cited by 58

Molecular Determinants of Tumor Recurrence in The Urinary Bladder

Liang Cheng, C., Zhang, S., Davidson, D. D., MacLennan, G. T., Koch, M. O., Montironi, R., & Antonio Lopez-beltran, B. (2009) · Future Oncology · doi:10.2217/fon.09.50 · Cited by 57

Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198–fibroblast growth factor receptor-1 chimeric tyrosine kinase

Ren, M., Li, X., & Cowell, J. K. (2009) · Blood · doi:10.1182/blood-2009-03-212704 · Cited by 56

Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis

Lu, M., Zessin, A. S., Glover, W., & Hsu, D. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169439 · Cited by 56

eIF4E Phosphorylation in Prostate Cancer

D'Abronzo, L. S., & Ghosh, P. (2018) · Neoplasia · doi:10.1016/j.neo.2018.04.003 · Cited by 56

mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer

Chen, X., Cheng, H., Pan, T., Liu, Y., Yang, S., Ren, C., Huang, D., Zha, X., & Liang, C. Y. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22177 · Cited by 55

Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis

Arai, H., Ueno, T., Tangoku, A., Yoshino, S., Abe, T., Kawauchi, S., Oga, A., Furuya, T., Oka, M., & Sasaki, K. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00106-7 · Cited by 55

Exome Sequencing Reveals De Novo Germline Mutation of the Mammalian Target of Rapamycin (MTOR) in a Patient with Megalencephaly and Intractable Seizures

(2013) · Journal of Genomes and Exomes · doi:10.4137/jge.s12583 · Cited by 53

Folliculin regulates mTORC1/2 and WNT pathways in early human pluripotency

Mathieu, J., Detraux, D., Kuppers, D. A., Wang, Y., Cavanaugh, C., Sidhu, S. B., Levy, S., Robitaille, A. M., Ferreccio, A., Bottorff, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08020-0 · Cited by 52

Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS- Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network

Chatterjee, S., Huang, E. H. ‐., Christie, I., Kurland, B. F., & Burns, T. F. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0677 · Cited by 50

A germline MTOR mutation in Aboriginal Australian siblings with intellectual disability, dysmorphism, macrocephaly, and small thoraces

Baynam, G. S., Overkov, A., Davis, M. R., Mina, K., Schofield, L., Allcock, R. J. N., Laing, N. G., Cook, M., Dawkins, H. J. S., & Goldblatt, J. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37070 · Cited by 49

Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway

Liu, X., Tan, X., Liu, P., Wu, Y., Qian, S., & Zhang, X. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15166223632406 · Cited by 49

The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial–mesenchymal transition induced by hypoxia and TGF-β1

Lin, G., Gai, R., Chen, Z., Wang, Y., Liao, S., Dong, R., Zhu, H., Gu, Y., He, Q., & Yang, B. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.02.011 · Cited by 48

Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*

Murugan, A. K., Alzahrani, A. S., & Xing, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399485 · Cited by 47

p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma

Wu, D., Cheng, J., Sun, G., Wu, S., Li, M., Gao, Z., Zhai, S., Li, P., Su, D., & Wang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9282 · Cited by 46

Inhibiting 4EBP1 in Glioblastoma

Fan, Q. W., Nicolaides, T. P., & Weiss, W. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0042 · Cited by 45

Cell type–specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors

Hsieh, A. C., Nguyen, H. G., Wen, L., Edlind, M. P., Carroll, P. R., Kim, W. K., & Ruggero, D. (2015) · Science Signaling · doi:10.1126/scisignal.aad5111 · Cited by 42

Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance

Liu, W., Chang, J., Liu, M., Yuan, J., Zhang, J., Qin, J., Xia, X., & Wang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.17415 · Cited by 41

Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β‐catenin‐EGFR‐PI3K‐Akt‐mTOR signaling pathway

Zhang, B., Deng, C., Wang, L., Zhou, F., Zhang, S., Kang, W., Zhan, P., Chen, J., Shen, S., Guo, H., et al. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22747 · Cited by 40

ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition

Ruicci, K. M., Pinto, N. C., Khan, M. I., Yoo, J., Fung, K., MacNeil, S. D., Mymryk, J. S., Barrett, J. W., & Nichols, A. C. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.07.010 · Cited by 38

Function of erbB receptors and DNA-PKcs on phosphorylation of cytoplasmic and nuclear Akt at S473 induced by erbB1 ligand and ionizing radiation

Toulany, M., Schickfluß, T.-A., Fattah, K. R., Lee, K. J., Chen, B. P. C., Fehrenbacher, B., Schaller, M., Chen, D. J., & Rodemann, H. P. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.06.004 · Cited by 35

Identification and characterization of two novel oncogenic mTOR mutations

Murugan, A. K., Liu, R., & Xing, M. (2019) · Oncogene · doi:10.1038/s41388-019-0787-5 · Cited by 35

Activating Mutations in TOR Are in Similar Structures As Oncogenic Mutations in PI3KCα

Sturgill, T. W., & Hall, M. N. (2009) · ACS Chemical Biology · doi:10.1021/cb900193e · Cited by 34

Targeting PI3K/Akt signal transduction for cancer therapy

He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 2,045

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?

Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 810

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 818

Targeting mTOR for cancer therapy

Hua, H. M., Kong, Q., Zhang, H., Wang, J., Luo, T. L., & Jiang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 929

Current treatment strategies for inhibiting mTOR in cancer

Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 279

Tests génétiques, le cadre législatif en France et en Europe

Delpech, M. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81765-2

Polymorphisme – 493 G/T du gène de la microsomal triglycéride transfer protein et infarctus du myocarde chez une population tunisienne

Jemaa, R., Abid, M., Kallel, A., Chabrak, S., Mn, K., Elasmi, M., Feki, M., & Kaabachi, N. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)81788-3

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11